2024-03-01 12:45:04 ET
DENVER, Colo., Mar 01, 2024 ( 247marketnews.com )- Myomo, Inc. (NYSE: MYO ) reported, this morning, that the Centers for Medicare & Medicaid Services (CMS) posted the final Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) fee schedule payment rates for its MyoPro. The CMS posted the the final fees yesterday, which become effective on April 1, 2024.
MYO is trading at $3.85, up $0.79 (+25.82%), on over 1.55 million shares.
Its 52-week range is $0.371 to $5.58 and today’s range is $3.2036 to $4.00. Its 30 day average volume is 607,153.
“We’re extremely gratified to have reached a successful conclusion with CMS, a process that started in 2018 with the granting of the two HCPCS billing codes,” stated Paul R. Gudonis, Myomo’s Chairman and CEO. “This is an important milestone for qualified Medicare Part B beneficiaries with long-term muscular weakness or partial paralysis, and for Myomo as a company. We extend thanks to the personnel at CMS for their efforts and for appreciating the benefits that powered braces such as the MyoPro can provide to Medicare Part B beneficiaries. ”
The about section states that “Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com. ”
() discussed in this article.
The post CMS Posts CMS Fee Schedule Rate for its MyoPro appeared first on 24/7 MarketNews .
For further details see:
CMS Posts CMS Fee Schedule Rate for its MyoPro